| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
43,990,000 |
| Market
Cap: |
369.08(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$5.31 - $14.39 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile REGENXBIO is a clinical-stage biotechnology company. Co.'s product candidates include: RGX-314, which is being developed as a gene therapy for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other additional chronic retinal conditions which cause total or partial vision loss for patients in the U.S., Europe and Japan; RGX-121, which is for the treatment of Mucopolysaccharidosis Type II; RGX-111, which is for the treatment of Mucopolysaccharidosis Type I; RGX-181, which is for the treatment of late infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease; and RGX-381, which is for the treatment of ocular manifestations of CLN2 disease.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
20,602 |
20,602 |
111,450 |
291,565 |
| Total Sell Value |
$163,046 |
$163,046 |
$1,357,058 |
$4,680,268 |
| Total People Sold |
1 |
1 |
3 |
4 |
| Total Sell Transactions |
1 |
1 |
12 |
20 |
| End Date |
2025-03-30 |
2024-12-27 |
2024-06-28 |
2023-06-29 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Tasse Daniel |
|
– • – |
2025-05-30 |
4 |
A |
$0.00 |
$0 |
D/D |
7,768 |
19,054 |
|
- |
|
| Stump David C |
|
– • – |
2025-05-30 |
4 |
A |
$0.00 |
$0 |
D/D |
7,768 |
19,054 |
|
- |
|
| Migausky George V |
|
– • – |
2025-05-30 |
4 |
A |
$0.00 |
$0 |
D/D |
7,768 |
19,054 |
|
- |
|
| Zachary Jennifer |
|
– • – |
2025-05-30 |
4 |
A |
$0.00 |
$0 |
D/D |
7,768 |
22,064 |
|
- |
|
| Bennett Jean |
|
– • – |
2025-05-30 |
4 |
A |
$0.00 |
$0 |
D/D |
7,768 |
19,054 |
|
- |
|
| Karabelas Argeris N |
|
– • – |
2025-05-30 |
4 |
A |
$0.00 |
$0 |
D/D |
7,768 |
19,054 |
|
- |
|
| Glucksmann Alexandra |
|
– • – |
2025-05-30 |
4 |
A |
$0.00 |
$0 |
D/D |
7,768 |
19,054 |
|
- |
|
| Mills Kenneth T. |
|
– • – |
2025-05-30 |
4 |
A |
$0.00 |
$0 |
D/D |
7,768 |
482,871 |
|
- |
|
| Fox Allan M. |
|
– • – |
2025-05-30 |
4 |
A |
$0.00 |
$0 |
D/D |
7,768 |
19,054 |
|
- |
|
| Mills Kenneth T. |
|
– • – |
2025-05-12 |
4 |
AS |
$7.91 |
$163,046 |
D/D |
(20,602) |
475,103 |
|
5% |
|
| Mills Kenneth T. |
|
– • – |
2025-05-12 |
4 |
OE |
$3.76 |
$77,464 |
D/D |
20,602 |
495,705 |
|
- |
|
| Mills Kenneth T. |
|
– • – |
2025-03-27 |
4 |
OE |
$3.76 |
$115,628 |
D/D |
30,752 |
475,103 |
|
- |
|
| Malzahn Craig |
Chief Technology Officer |
• – – |
2025-03-13 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
17,819 |
|
28% |
|
| Christmas Patrick J. |
Chief Legal Officer |
• – – |
2025-02-01 |
4 |
D |
$8.07 |
$37,929 |
D/D |
(4,700) |
156,110 |
|
- |
|
| Danos Olivier |
Chief Scientific Officer |
• – – |
2025-02-01 |
4 |
D |
$8.07 |
$43,998 |
D/D |
(5,452) |
226,348 |
|
- |
|
| Pakola Steve |
Chief Medical Officer |
• – – |
2025-02-01 |
4 |
D |
$8.07 |
$42,472 |
D/D |
(5,263) |
210,717 |
|
- |
|
| Christmas Patrick J. |
Chief Legal Officer |
• – – |
2025-01-02 |
4 |
D |
$7.73 |
$88,083 |
D/D |
(11,395) |
160,810 |
|
- |
|
| Simpson Curran |
Chief Executive Officer |
• • – |
2025-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
98,912 |
257,032 |
|
- |
|
| Simpson Curran |
Chief Executive Officer |
• • – |
2025-01-02 |
4 |
D |
$7.73 |
$92,118 |
D/D |
(11,917) |
158,120 |
|
- |
|
| Danos Olivier |
Chief Scientific Officer |
• – – |
2025-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
59,347 |
231,800 |
|
- |
|
| Danos Olivier |
Chief Scientific Officer |
• – – |
2025-01-02 |
4 |
D |
$7.73 |
$97,630 |
D/D |
(12,630) |
172,453 |
|
- |
|
| Pakola Steve |
Chief Medical Officer |
• – – |
2025-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
64,293 |
215,980 |
|
- |
|
| Pakola Steve |
Chief Medical Officer |
• – – |
2025-01-02 |
4 |
D |
$7.73 |
$107,377 |
D/D |
(13,891) |
151,687 |
|
- |
|
| Karabelas Argeris N |
|
– • – |
2024-10-01 |
4 |
AS |
$10.11 |
$101,052 |
D/D |
(10,000) |
11,286 |
|
-28% |
|
| Karabelas Argeris N |
|
– • – |
2024-10-01 |
4 |
OE |
$3.76 |
$37,600 |
D/D |
10,000 |
21,286 |
|
- |
|
464 Records found
|
|
Page 1 of 19 |
|
|
0.36 (4.11%) 
